Laboratory Testing for the Evaluation of Phenotypic Activated Protein C Resistance.


Journal

Seminars in thrombosis and hemostasis
ISSN: 1098-9064
Titre abrégé: Semin Thromb Hemost
Pays: United States
ID NLM: 0431155

Informations de publication

Date de publication:
Sep 2022
Historique:
entrez: 12 10 2022
pubmed: 13 10 2022
medline: 15 10 2022
Statut: ppublish

Résumé

Activated protein C (APC) resistance (APCR) is considered a risk factor of venous thromboembolism (VTE). The most common genetic disorder conferring APCR is a factor (F) V Leiden mutation, but many other factors are also implicated, such as other

Identifiants

pubmed: 36223771
doi: 10.1055/s-0042-1758162
doi:

Substances chimiques

Hormones 0
Protein C 0
Factor V 9001-24-5
Factor VIII 9001-27-8
Thrombin EC 3.4.21.5

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

680-689

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

Dr. Bouvy reports other from QUALIblood, during the conduct of the study; Dr. Douxfils reports other from Qualiblood, during the conduct of the study; personal fees from Stago Diagnostica, personal fees from Daiichi-Sankyo, personal fees from Portola, personal fees from Roche, personal fees from Roche Diagnostics, personal fees from DOASENSE, personal fees from Mithra Pharmaceuticals, personal fees from Estetra, personal fees from Werfen, personal fees from Technoclone, outside the submitted work; Dr. Morimont reports other from QUALIblood, during the conduct of the study; and Dr. Donis reports other from QUALIblood, during the conduct of the study. The remaining authors do not report any conflicts of interests.

Auteurs

Laure Morimont (L)

Department of Research, Qualiblood Sa, Namur, Belgium.
Department of Pharmacy, Faculty of Medicine, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.

Nathalie Donis (N)

Department of Research, Qualiblood Sa, Namur, Belgium.

Céline Bouvy (C)

Department of Research, Qualiblood Sa, Namur, Belgium.

François Mullier (F)

Hematology Laboratory, Namur Research Institute for Life Sciences (NARILIS), Namur Thrombosis and Hemostasis Center (NTHC), Université Catholique de Louvain, CHU UCL Namur, Yvoir, Belgium.

Jean-Michel Dogné (JM)

Department of Pharmacy, Faculty of Medicine, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.

Jonathan Douxfils (J)

Department of Research, Qualiblood Sa, Namur, Belgium.
Department of Pharmacy, Faculty of Medicine, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), University of Namur, Namur, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH